Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Document › Details

High-Tech Gründerfonds Management GmbH. (12/18/18). "Press Release: High-Tech Gründerfonds and Think.Health Ventures together with Business Angels Invest 3.3 Million Euros in a Series A for the Growth of PreOmics in Martinsried, Germany".

Region Region United States (USA)
Organisations Organisation High-Tech Gründerfonds Management GmbH
  Group High-Tech Gründerfonds (HTGF) (Group)
  Organisation 2 PreOmics GmbH
  Group Bruker (Group)
Products Product mass spectrometry reagents
  Product 2 venture capital
Index term Index term PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels
Persons Person Pichler, Garwin (PreOmics GmbH 201601– Managing Director + Co-Founder)
  Person 2 Mohr, Fabian (High-Tech Gründerfonds 201811)

PreOmics develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry. Today, the processing of samples for mass spectrometry is usually carried out according to homemade protocols. These processes are slow, not reproducible, not robust and cannot be automated. These solutions are therefore very time-consuming and costly, which can lead to the loss of valuable samples.

PreOmics addresses these problems with a standardized technology that enables robust and reproducible results in sample preparation. In addition, the protocols have a significantly reduced workload compared to conventional methods. As part of the seed investment with High-Tech Gründerfonds and Business Angels, the first products were launched on the market and new products developed. The founders Garwin Pichler and Nils Kulak established a team in the facilities of the IZB in Martinsried and formed partnerships for production and further development. Think Health Ventures is now leading another financing round of 3.3 million euros to support the further internationalization of the business and the development of further products.

Dr. Garwin Pichler, Managing Director at PreOmics: “Customers worldwide use our technologies that enable standardized and efficient sample preparation for protein analysis and offer a significant cost-benefit advantage. With the new capital, we want to accelerate the expansion of our global distribution with a focus on the USA and the development of new products”.

Dr. Fabian Mohr, Investment Manager at HTGF: “We are very excited to be investing in Series A to continue the success of the Seed Round. The company has made a great development and we rely on the leadership team for further market expansion and product development”.

For Dr. Michael Ruoff, Partner at Think Health Ventures, “the effective solution of a clear problem with positive market feedback combined with the expertise and ambition of the entire team” was essential for the investment. “With PreOmics, we see great potential to accelerate drug development for serious diseases, as PreOmics’ products currently have a second-to-nonemarket position”.

About PreOmics

The company was founded in August 2016 with Intellectual Property from Matthias Mann’s laboratory at the Max Planck Institute for Biochemistry. Since then, new products have been developed which have been protected with their own IP. The managing directors Garwin Pichler and Nils Kulak are supported by an advisory board with a wealth of experience in the life sciences. PreOmics’ mission is to bring the gold standard for pre-analytics in mass spectrometry to the market.

PreOmics GmbH
Am Klopferspitz 19
82152 Planegg-Martinsried
T: +49 89 23 14 163 0

About High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 892.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge 500 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, hardware and life sciences / chemistry.

To date, external investors have injected over EUR 1.9 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

High-Tech Gründerfonds Management GmbH
Dr. Fabian Mohr
Schlegelstraße 2
53113 Bonn
T: +49 228 82300 181

About Think Health Ventures

Think.Health Ventures invests in companies in the healthcare and life science sectors. Through active support and a broad network, the portfolio companies are supported and promoted in their development. The Think.Health Ventures team combines many years of experience in hospital management, healthcare and M&A transactions.

Dr. Florian Kainzinger

Record changed: 2023-06-05


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for High-Tech Gründerfonds (HTGF) (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top